A company on the exchange co-invests with a provincial hospital, enthusiastically opens a chain of clinics and testing centers nationwide, with stock prices at “tea glass” levels

Sara Vietnam Joint Stock Company (SRA) is heavily investing in clinics and testing labs, targeting growth potential in healthcare services in Vietnam. Since 2019, SRA has invested more than 204 billion VND in the Phu Tho General Hospital and in 2024, it’s continuing with nearly 20 billion VND into Medicare Clinics across 4 provinces, along with other specialized clinics nationwide. Although facing challenges in medical waste treatment, SRA shows a pivot in business strategy with Q4 2024 revenue surging by 1,584% year-on-year to nearly 98 billion VND, with a post-tax profit of around 40 billion VND, 25 times higher than last year. The full year 2024 profit reached 28 billion VND, almost 6 times 2023. However, SRA shares are currently trading at 3,200 VND/share, equivalent to “tea glass” levels, and face trading restrictions due to warnings from HNX.